Jul 20, 2021, 10:29 PM ETInterview

Rick Doblin: Psychedelics | Lex Fridman Podcast #202

Broad Definition: "Psychedelic" (mind-manifesting) encompasses any state that brings subconscious material to the surface, including dreams, hyperventilation, meditation, and chemical substances.
Two Primary Categories:
- Classic Psychedelics: Agents like LSD, psilocybin, mescaline, ayahuasca, and DMT that induce ego dissolution and unitive states by weakening the brain's "reducing valve" (filtering function).
- Empathogens/Intactogens: Agents like MDMA that strengthen the sense of self, increase empathy, and reduce amygdala activity (fear processing) without causing ego dissolution.
Neurobiological Action:
- Classic psychedelics (e.g., 5-MeO-DMT, LSD) reduce energy flow in the Default Mode Network (DMN), allowing floods of information from non-conscious processing and shifting cognition from verbal to symbolic thinking.
- MDMA increases connectivity between the amygdala and hippocampus, facilitating the storage of traumatic memories into long-term, non-fearful contexts.
Substance Origins: There is no inherent moral or safety distinction between natural substances (e.g., psilocybin mushrooms) and synthetic ones (e.g., LSD, MDMA); both can be therapeutic or harmful depending on context.
Duration Variance:
- DMT (smoked): 10–15 minutes.
- 5-MeO-DMT: Rapid onset, very short duration.
- Psilocybin: 4–6 hours.
- LSD: 8–12 hours.
- MDMA: ~4 hours (extended via supplemental dosing in therapy).

Project MKUltra: A CIA program that secretly dosed citizens with LSD for interrogation and mind-control research; it violated human rights but inadvertently inspired the 1960s counterculture and psychedelic research (e.g., Ken Kesey, The Grateful Dead).
Ken Kesey: Attributed his creative output on One Flew Over the Cuckoo's Nest to LSD-induced "semantic priming," which expanded his associative range and access to metaphorical imagery.
The Unabomber (Ted Kaczynski): Rick Doblin confirms Kaczynski was exposed to MKUltra and argues his radicalization resulted from the context of the experience rather than the drug itself, contrasting with the positive outcomes seen in Ken Kesey.
Timothy Leary's Role:
- Conducted the Good Friday Experiment (1962) showing religiously inclined individuals could have mystical experiences via psilocybin.
- Conducted the Concord Prison Experiment, which Leary later admitted to fudging data for to counteract the FDA's over-estimation of risks.
- Advocated for "Turn on, tune in, drop out," which paradoxically mobilized political resistance to the Vietnam War and status quo.

Organizational Structure: MAPS is a non-profit that established a MAPS Public Benefit Corporation in 2014 to market drugs; the corporation is 100% owned by the non-profit to maximize public benefit rather than shareholder profit.
Mission: "Mass mental health" to spiritualize humanity and end the drug war, focusing on drug development and policy reform rather than pure academic research.
Regulatory Innovation: Utilized a 1984 Reagan-signed bill to secure data exclusivity (5.5 years in the US) for MDMA, allowing the organization to recoup research costs via sales without patenting the molecule itself.
Funding: Raised ~$110 million in donations over 35 years; projected to generate up to $750 million in profits during the exclusivity period from the first MDMA approval.

Phase 3 Study Results (Published in Nature Medicine):
- Efficacy: A 2.1 effect size (within-group) and 0.91 placebo-subtracted effect size, significantly outperforming SSRIs (0.3–0.4 effect size).
- Significance: Achieved a p-value of 0.0001 (1 in 10,000 chance of random error), considered "robust" enough to potentially bypass the need for a second Phase 3 study.
- Durability: 67% of the MDMA group no longer met PTSD criteria at the 12-month mark, compared to 32% in the placebo group.
Safety and Side Effects:
- No neurotoxicity observed in therapeutic doses; cognitive function remained stable.
- Side effects (sweating, jaw clenching) were transient and minor.
- Suicide Risk: Both suicide attempts during the study occurred in the placebo group, suggesting MDMA may increase hope and safety.
Study Design Challenges:
- The "double-blind" problem was unsolvable for high-dose MDMA as patients and therapists could easily distinguish the drug from a low-dose or inactive placebo.
- Solution: Relied on an independent rater pool (>20 raters) to evaluate symptoms via blinded video reviews, ensuring objectivity despite the inability to blind participants.
Target Population: Successfully treated the dissociative subtype of PTSD (the hardest to treat), demonstrating MDMA helps reverse dissociation by reducing fear and enhancing memory integration.

Timeline for Access:
- Late 2023: Anticipated FDA approval for MDMA-assisted therapy for PTSD (prescription only).
- 2023–2025: Likely approval for Psilocybin for depression and anxiety.
- 2035: Projected date for licensed legalization, allowing supervised, personal-use access without medical necessity.
Commercialization Model:
- MAPS advocates for psychedelic clinics staffed by therapists, contrasting with the "ketamine mill" model (pharmaceuticals without therapy) used by profit-driven companies like Johnson & Johnson.
- Concerns raised that for-profit companies may prioritize volume over therapeutic depth, potentially reducing efficacy.
Global Potential:
- Ibogaine: High potential for treating opiate addiction.
- Psilocybin: Promising for life-threatening illness anxiety and addiction (tobacco).
Cultural Vision:
- Goal of "Net Zero Trauma" by 2050, aiming to cleanse societal filters to recognize shared humanity.
- Advocates for a shift in worldview where religions are seen as diverse "languages" rather than exclusive truths, reducing tribalism.

Nature of Experience: Psychedelics do not conjure new information but reveal pre-existing subconscious material (traumas, ancestral memories, or "collective unconscious" resonances) previously filtered out by the ego.
Context is Paramount: The outcome of a psychedelic experience is determined by set (mindset) and setting (environment), not the molecule alone; safety and support are prerequisites for therapeutic success.
Life and Death: Death is viewed as essential for giving life intensity and value; infinite life would remove the urgency to act, as "the end makes things precious."
Advice for Youth: Find the intersection between personal passion ("what makes you come alive") and world needs, prioritizing long-term impact over immediate resource acquisition.